Showing 7651-7660 of 8649 results for "".
- Kubota Vision Provides Update on Kubota Glasses—Wearable Device for Myopia Controlhttps://modernod.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/Kubota Vision announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology. Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glass
- Demand, Pay for Travel ICU Nurses Soar as Hospitals Face Staff Crunch Due to COVID-19https://modernod.com/news/demand-pay-for-travel-icu-nurses-soar-as-hospitals-face-staff-crunch-due-to-covid-19/2478681/Staffing crunches caused by COVID-19 created a massive 305% increase in demand for intensive care unit travel nurses from March to November, according to a new report, as
- Oyster Point Submits NDA to FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-submits-nda-to-fda-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478677/Oyster Point Pharma announced it has submitted a 505(b)(2) new drug application (NDA) to the FDA for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The NDA submission is supported by safety and efficacy results from the phase 3 ONSET-2, phase 2b ONSET-
- FDA Panel Endorses Moderna’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/fda-panel-endorses-modernas-covid-19-vaccine-for-emergency-use/2478678/An FDA advisory panel on Thursday voted 20-0, with one abstention, that the benefits of Moderna’s COVID-19 vaccine mRNA-1273 outweigh its risks in people 18 years and older. The panel backing sets the stage for the FDA to issue an emergency-use authorization (EUA) for the candidate, which i
- Influx of New Contact Lens Patients Calls for Simplified Wear-and-Care Educationhttps://modernod.com/news/influx-of-new-contact-lens-patients-calls-for-simplified-wear-and-care-education/2478671/Within days of mask guidelines being implemented earlier this year, the reports of fogging started streaming in from glasses and sunglasses wearers. Social feeds were soon packed with photos of the annoying condensation and news reports began offering tips on how to avoid condensation. In 2020, t
- Vaccine Rollout On Track, Expect 300M Doses Through March: Fedshttps://modernod.com/news/vaccine-rollout-on-track-expect-300m-doses-through-march-feds/2478672/If the initial success of the Pfizer-BioNTech rollout continues, and emergency use authorization (EAU) is granted to Moderna and Johnson & Johnson vaccines in development, Operation Warp Speed officials expect to have 300 million doses of COVID-19 vaccines to distribute across the United Stat
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitishttps://modernod.com/news/nicox-initiates-phase-2b-trial-of-ncx-4251-a-potential-first-in-class-treatment-for-blepharitis/2478662/Nicox SA announced the initiation of the Mississippi trial, a phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis. NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystal
- Novartis Reports Positive Topline Results From Second Phase 3 Trial of Beovu in Patients With DMEhttps://modernod.com/news/novartis-reports-positive-topline-results-from-second-phase-3-trial-of-beovu-in-patients-with-dme/2478658/Novartis announced positive findings from the first interpretable results of the phase 3 KESTREL study, assessing the efficacy and safety of Beovu (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME). Following KITE, KESTREL is the second pivotal phase 3 study of Beovu in DME. The
- Bruder Introduces Pre-Surgical Patient Prep Kithttps://modernod.com/news/bruder-introduces-pre-surgical-patient-prep-kit/2478655/Bruder has introduced the Bruder Sx Pre-Surgical Patient Prep Kit, which allow patients’ hygiene products to be available in a single, self-contained kit. Doctors can provide the kit directly in their practices